26.8 C
New York
Thursday, July 3, 2025

Tag: investigations

APPLOVIN ALERT: Bragar Eagel & Squire, P.C. is Investigating AppLovin Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against AppLovin Corporation (NASDAQ:APP) on behalf of long-term stockholders following a class action complaint that was filed against AppLovin on March 5, 2025 with a Class Period from May 10, 2023 to March 26, 2025.. Our investigation concerns whether the board of directors of AppLovin have breached their fiduciary duties to the company.

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer 

LASER PHOTONICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Laser Photonics Corporation on Behalf of Laser Photonics Stockholders and Encourages Investors to Contact...

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Laser Photonics Corporation (“Laser Photonics” or the “Company”) (NASDAQ:LASE) on behalf of Laser Photonics stockholders. Our investigation concerns whether Laser Photonics has violated the federal securities laws and/or engaged in other unlawful business practices.

EZGO ANNOUNCES FINANCIAL RESULTS FOR THE SIX MONTHS ENDED MARCH 31, 2025

CHANGZHOU, China, July 1, 2025 /PRNewswire/ -- EZGO Technologies Ltd. (Nasdaq: EZGO) ("EZGO" or "we", "our", or the "Company"), a leading short-distance transportation solutions...

CENTENE CORPORATION WITHDRAWS 2025 GUIDANCE

ST. LOUIS, July 1, 2025 /PRNewswire/ -- Centene Corporation (NYSE: CNC) (Centene, the Company) is withdrawing its previous 2025 GAAP and adjusted diluted earnings per...

Relm Appoints Dr Rayyan Zafar As Senior Scientific Advisor As Part Of Strategic Expansion In Alternative Therapeutics Sector

Bermuda, July 01, 2025 (GLOBE NEWSWIRE) -- - Relm Insurance (‘Relm’), the leading insurer for emerging and innovative industries, today announced the appointment of Dr. Rayyan Zafar, PhD, MRSB, as a Senior Scientific Advisor to the firm. In this role, Dr. Zafar will inform Relm’s strategic expansion into the emerging field of Psychedelics and Alternative Therapeutics, leveraging his world-class expertise to deepen Relm’s understanding of novel treatments for addiction and mental health disorders.

eToro Secures $250 Million Revolving Credit Facility

eToro Secures $250 Million Revolving Credit Facility

Glass Lewis Joins ISS in Raising Concerns About Ortelius’ Campaign at Brookdale

Proxy Advisory Firms Recommend Against Giving Ortelius Control of the Company's Board Brookdale Urges Shareholders to Vote "FOR" ALL of Brookdale's Eight Highly Qualified Director...

Trump’s Tariff Tantrum: Trade Deals Take a Nap

As the globe spins toward yet another round of economic brinkmanship, America's trading partners scramble to ink deals with the U.S., a move akin...

RDDT LAWSUIT DEADLINE: Suffer Losses on Reddit, Inc.? Contact BFA Law before the August 18 Securities Fraud Class Action Deadline (NYSE:RDDT)

Reddit, Inc. investors that lost money are notified to contact BFA Law before the August 18, 2025 securities fraud class action deadline.

Lottery.com Closes in on Legal Action Against Coordinated ‘Short and Distort’ Campaign

FORT WORTH, Texas, June 27, 2025 (GLOBE NEWSWIRE) -- Lottery.com Inc. (NASDAQ: LTRY, LTRYW) (“Lottery.com” or “the Company”), a leading technology company transforming the intersection of gaming, sports and entertainment, today confirmed that it is nearing legal proof of a coordinated and unlawful ‘short and distort’ campaign targeting the Company. In collaboration with its legal counsel, Paul Hastings LLP, the Company is actively pursuing all individuals and entities engaged in market manipulation intended to damage the Company’s share price and reputation.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq – VERV), Sage Therapeutics, Inc. (Nasdaq – SAGE), Cantaloupe,...

BALA CYNWYD, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder

Phase 3 study met primary and most key secondary clinical endpointsThis marks the third developmental and epileptic encephalopathies (DEE) population for fenfluramine with positive phase...

AVIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Avis Budget Group, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the...

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Avis Budget Group, Inc. (NASDAQ:CAR) on behalf of long-term stockholders following a class action complaint that was filed against Avis on April 25, 2025 with a Class Period from February 16, 2024 and February 10, 2025. Our investigation concerns whether the board of directors of Avis have breached their fiduciary duties to the company.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInvestigations